Why the study?
Does dalteparin reduce coagulation activation in pregnant women with thrombophilia?
Population
91 pregnant women at high risk of pregnancy complications with confirmed thrombophilia (85 analyzed)
Comparison
Dalteparin 5,000 units/day until 20 weeks then… vs No treatment
Design
RCT, randomized, open label
Follow-up
until 37 weeks or onset of labor
Authors
Loading...
Prophylactic dalteparin does not reduce coagulation activation markers in thrombophilic pregnancies; challenges presumed mechanism and supports reevaluating routine prophylaxis.
Does dalteparin reduce coagulation activation in pregnant women with thrombophilia?
Prophylactic dalteparin does not reduce coagulation activation markers in high-risk pregnant women with thrombophilia.
Abou-Nassar et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: